Macrophage migration inhibitory factor gene polymorphisms and plasma levels in children with obstructive sleep apnea

Pediatric Pulmonology

Volumn 47, Issue 10, 2012, Pages 1001-1011

  Khalyfa, Abdelnaby ^a   Kheirandish Gozal, Leila ^a   Capdevila, Oscar Sans ^a   Bhattacharjee, Rakesh ^a   Gozal, David ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

atherosclerosis; genomic variance; insulin resistance; MIF; polymorphisms; sleep apnea

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; MACROPHAGE MIGRATION INHIBITION FACTOR;

ALLELE; APNEA HYPOXIA INDEX; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP APNEA SYNDROME;

BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHILD; FASTING; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; INSULIN; INTRAMOLECULAR OXIDOREDUCTASES; LINKAGE DISEQUILIBRIUM; LIPIDS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYSOMNOGRAPHY; SLEEP APNEA, OBSTRUCTIVE;

EID: 84866241079     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22560     Document Type: Article

References (67)

1. O'Brien LM, Holbrook CR, Mervis CB, Klaus CJ, Bruner J, Raffield TJ, Rutherford J, Mehl RC, Wang M, Tuell A, Hume BC, Gozal D,. Sleep and neurobehavioral characteristics in 5-7-year-old hyperactive children. Pediatrics 2003; 111: 554-563.
2. Gozal D,. Obstructive sleep apnea in children: implications for the developing central nervous system. Semin Pediatr Neurol 2008; 15: 100-106.
3. Dayyat E, Kheirandish-Gozal L, Gozal D,. Childhood obstructive sleep apnea: one or two distinct disease entities ? Sleep Med Clin 2007; 2: 433-444.
4. Kheirandish-Gozal L, Bhattacharjee R, Kim J, Clair HB, Gozal D,. Endothelial progenitor cells and vascular dysfunction in children with obstructive sleep apnea. Am J Respir Crit Care Med 2010; 182: 92-97.
5. Bhattacharjee R, Kheirandish-Gozal L, Pillar G, Gozal D,. Cardiovascular complications of obstructive sleep apnea syndrome: evidence from children. Prog Cardiovasc Dis 2009; 51: 416-433.
6. Kheirandish-Gozal L, Bhattacharjee R, Gozal D,. Autonomic alterations and endothelial dysfunction in pediatric obstructive sleep apnea. Sleep Med 2010; 11: 714-720.
7. Bhattacharjee R, Kim J, Kheirandish-Gozal L, Gozal D,. Obesity and obstructive sleep apnea syndrome in children: a tale of inflammatory cascades. Pediatr Pulmonol 2011; 46: 313-323.
8. Khalyfa A, Capdevila OS, Buazza MO, Serpero LD, Kheirandish-Gozal L, Gozal D,. Genome-wide gene expression profiling in children with non-obese obstructive sleep apnea. Sleep Med 2009; 10: 75-86.
9. Khalyfa A, Gharib SA, Kim J, Capdevila OS, Kheirandish-Gozal L, Bhattacharjee R, Hegazi M, Gozal D,. Peripheral blood leukocyte gene expression patterns and metabolic parameters in habitually snoring and non-snoring children with normal polysomnographic findings. Sleep 2011; 34: 153-160.
10. Gozal D, Capdevila OS, Kheirandish-Gozal L,. Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children. Am J Respir Crit Care Med 2008; 177: 1142-1149.
11. Kim J, Lee S, Bhattacharjee R, Khalyfa A, Kheirandish-Gozal L, Gozal D,. Leukocyte telomere length and plasma catestatin and myeloid related protein 8/14 concentrations in children with obstructive sleep apnea. Chest 2010; 138: 91-99.
12. Edwards KM, Tomfohr LM, Mills PJ, Bosch JA, Ancoli-Israel S, Loredo JS, Dimsdale J,. Macrophage migratory inhibitory factor (MIF) may be a key factor in inflammation in obstructive sleep apnea. Sleep 2011; 34: 161-163.
13. Zernecke A, Bernhagen J, Weber C,. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594-1602.
14. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-596.
15. Calandra T, Roger T,. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
16. Kleemann R, Bucala R,. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010; 2010: 610479.
17. Toso C, Emamaullee JA, Merani S, Shapiro AM,. The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. Diabetologia 2008; 51: 1937-1946.
18. Wellen KE, Hotamisligil GS,. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
19. Benigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R,. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000; 106: 1291-1300.
20. Morand EF, Leech M, Bernhagen J,. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5: 399-410.
21. Bifulco C, McDaniel K, Leng L, Bucala R,. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 2008; 14: 3790-3801.
22. Nishihira J, Mitsuyama K,. Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease. Curr Pharm Des 2009; 15: 2104-2109.
23. Tierney T, Patel R, Stead CA, Leng L, Bucala R, Buckingham JC,. Macrophage migration inhibitory factor is released from pituitary folliculo-stellate-like cells by endotoxin and dexamethasone and attenuates the steroid-induced inhibition of interleukin 6 release. Endocrinology 2005; 146: 35-43.
24. Baugh JA, Donnelly SC,. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 2003; 179: 15-23.
25. Flex A, Gaetani E, Angelini F, Sabusco A, Chilla C, Straface G, Biscetti F, Pola P, Castellot JJ, Jr., Pola R,. Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med 2007; 262: 124-130.
26. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, Tondi P, Pola P, Pola R,. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35: 2270-2275.
27. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R,. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3: 170-176.
28. Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, Donn R,. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003; 4: 487-491.
29. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, Meazza C, De Benedetti F, Thomson W, Ray D,. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004; 50: 1604-1610.
30. Montgomery-Downs HE, O'Brien LM, Gulliver TE, Gozal D,. Polysomnographic characteristics in normal preschool and early school-aged children. Pediatrics 2006; 117: 741-753.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
32. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
33. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA,. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
34. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1: 107-119.
35. Gozal D, Kheirandish-Gozal L,. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008; 177: 369-375.
36. Tauman R, Ivanenko A, O'Brien LM, Gozal D,. Plasma C-reactive protein levels among children with sleep-disordered breathing. Pediatrics 2004; 113: e564-e569.
37. Larkin EK, Rosen CL, Kirchner HL, Storfer-Isser A, Emancipator JL, Johnson NL, Zambito AM, Tracy RP, Jenny NS, Redline S,. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111: 1978-1984.
38. Kaditis AG, Alexopoulos EI, Kalampouka E, Kostadima E, Germenis A, Zintzaras E, Gourgoulianis K,. Morning levels of C-reactive protein in children with obstructive sleep-disordered breathing. Am J Respir Crit Care Med 2005; 171: 282-286.
39. Kheirandish L, Gozal D,. Neurocognitive dysfunction in children with sleep disorders. Dev Sci 2006; 9: 388-399.
40. Villa MP, Ianniello F, Tocci G, Evangelisti M, Miano S, Ferrucci A, Ciavarella GM, Volpe M,. Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep Breath 2012; 16: 101-110.
41. Goldbart AD, Levitas A, Greenberg-Dotan S, Ben Shimol S, Broides A, Puterman M, Tal A,. B-type natriuretic peptide and cardiovascular function in young children with obstructive sleep apnea. Chest 2010; 138: 528-535.
42. Hoi AY, Iskander MN, Morand EF,. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6: 183-190.
43. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C,. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002; 105: 1561-1566.
44. Weber C, Schober A, Zernecke A,. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008.
45. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, Lau CP, Lan HY,. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 2000; 87: 1202-1208.
46. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, Mizue Y, Bucala R, Simon D,. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 709-714.
47. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004; 109: 3149-3153.
48. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C,. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 2004; 109: 380-385.
49. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R,. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994; 33: 14144-14155.
50. Herder C, Klopp N, Baumert J, Muller M, Khuseyinova N, Meisinger C, Martin S, Illig T, Koenig W, Thorand B,. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia 2008; 51: 276-284.
51. Greven D, Leng L, Bucala R,. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets 2010; 14: 253-264.
52. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R,. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68-71.
53. Metz CN, Bucala R,. Role of macrophage migration inhibitory factor in the regulation of the immune response. Adv Immunol 1997; 66: 197-223.
54. Morand EF, Leech M,. Glucocorticoid regulation of inflammation: the plot thickens. Inflamm Res 1999; 48: 557-560.
55. Lam DC, Xu A, Lam KS, Lam B, Lam JC, Lui MM, Ip MS,. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur Respir J 2009; 33: 346-351.
56. Khalyfa A, Bhushan B, Hegazi M, Kim J, Kheirandish-Gozal L, Bhattacharjee R, Capdevila OS, Gozal D,. Fatty-acid binding protein 4 gene variants and childhood obesity: potential implications for insulin sensitivity and CRP levels. Lipids Health Dis 2010; 9: 18.
57. Sakaue S, Ishimaru S, Hizawa N, Ohtsuka Y, Tsujino I, Honda T, Suzuki J, Kawakami Y, Nishihira J, Nishimura M,. Promoter polymorphism in the macrophage migration inhibitory factor gene is associated with obesity. Int J Obes (Lond) 2006; 30: 238-242.
58. Choi HJ, Cho HY, Ro H, Lee SH, Han KH, Lee H, Kang HG, Ha IS, Choi Y, Cheong HI,. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol 2011; 26: 1981-1988.
59. Aslani S, Hossein-Nezhad A, Maghbooli Z, Mirzaei K, Karimi F,. Genetic variation in macrophage migration inhibitory factor associated with gestational diabetes mellitus and metabolic syndrome. Horm Metab Res 2011; 43: 557-561.
60. Simonini G, Corinaldesi E, Massai C, Falcini F, Fanti F, De Martino M, Cimaz R,. Macrophage migration inhibitory factor -173 polymorphism and risk of coronary alterations in children with Kawasaki disease. Clin Exp Rheumatol 2009; 27: 1026-1030.
61. Awandare GA, Ouma C, Keller CC, Were T, Otieno R, Ouma Y, Davenport GC, Hittner JB, Ong'echa JM, Ferrell R, et al. A macrophage migration inhibitory factor promoter polymorphism is associated with high-density parasitemia in children with malaria. Genes Immun 2006; 7: 568-575.
62. Prencipe G, Auriti C, Inglese R, Devito R, Ronchetti MP, Seganti G, Rava L, Orzalesi M, De Benedetti F,. A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. Pediatr Res 2011; 69: 142-147.
63. Shiroeda H, Tahara T, Shibata T, Nakamura M, Yamada H, Nomura T, Hayashi R, Saito T, Fukuyama T, Otsuka T, et al. Functional promoter polymorphisms of macrophage migration inhibitory factor in peptic ulcer diseases. Int J Mol Med 2010; 26: 707-711.
64. Martin RJ, Savage DA, Carson DJ, McKnight AJ, Maxwell AP, Patterson CC,. Polymorphisms of the macrophage migration inhibitory factor gene in a UK population with type 1 diabetes mellitus. Diabet Med 2010; 27: 143-149.
65. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Torres O, Miranda-Filloy JA, Llorca J, Martin J, Gonzalez-Gay MA,. Lack of association between macrophage migration inhibitory factor -173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clin Exp Rheumatol 2010; 28: 68-72.
66. Akyildiz M, Gunsar F, Nart D, Sahin O, Yilmaz F, Akay S, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 192-198.
67. Wu J, Fu S, Ren X, Jin Y, Huang X, Zhang X, Bai J,. Association of MIF promoter polymorphisms with childhood asthma in a northeastern Chinese population. Tissue Antigens 2009; 73: 302-306.